PALB2 Polyclonal Antibody [AT126]
- Known as:
- PALB2 Polyclonal Antibody [AT126]
- Catalog number:
- A-0505-100
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- EpigenTek
- Gene target:
- PALB2 Polyclonal Antibody [AT126]
Related genes to: PALB2 Polyclonal Antibody [AT126]
- Gene:
- PALB2 NIH gene
- Name:
- partner and localizer of BRCA2
- Previous symbol:
- -
- Synonyms:
- FLJ21816, FANCN
- Chromosome:
- 16p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 2007-01-15
- Date modifiied:
- 2019-04-23
Related products to: PALB2 Polyclonal Antibody [AT126]
Related articles to: PALB2 Polyclonal Antibody [AT126]
- Due to the expansion of knowledge about genetic predispositions to breast cancer, the International Hereditary Cancer Center in Szczecin has been solicited to update the Polish ministerial guidelines for the qualification of patients who should be offered prophylactic mastectomy. - Source: PubMed
Publication date: 2026/06/04
Stachowski AdamCybulski CezaryGronwald JacekHuzarski TomaszDębniak TadeuszByrski TomaszNarod StevenScott RodneyLubiński Jan - The emerging focus on epigenetic regulation in cancer biology has unveiled the significant role of CXorf67, a protein encoded by a gene on the X chromosome. CXorf67 interacts with core components of PRC2, namely EZH2 and SUZ12, thereby influencing histone modifications like H3K27me3. Research indicates that CXorf67 is overexpressed in specific malignancies, including posterior fossa ependymomas, diffuse midline glioma, endometrial stromal sarcoma, non-small cell lung cancer, and Merkel cell carcinoma. In posterior fossa ependymomas and diffuse midline glioma, CXorf67 mimics the oncogenic histone H3K27M, inhibiting PRC2 function and altering chromatin states. In endometrial stromal sarcoma, CXorf67 forms fusion genes with MBTD1, potentially disrupting polycomb group (PcG) functions. Additionally, CXorf67's interaction with PALB2 affects the BRCA1-PALB2-BRCA2 complex, influencing DNA repair mechanisms. These findings highlight CXorf67's dual role in epigenetic regulation and DNA damage response, suggesting its potential as a therapeutic target. However, further research is needed to explore its functions in other cancers and clarify its molecular mechanisms. Our review synthesizes current knowledge on CXorf67's biological significance, particularly in epigenetics and DNA damage, and its implications in oncogenesis. - Source: PubMed
Publication date: 2025/11/10
Yu XinningWu HuataoLan YangzhengChen WenjiaLiu Jing - All breast cancer (BC) patients have a risk of developing contralateral BC (CBC). This will be higher in women carrying a BC susceptibility gene pathogenic variant (PV), but specific risk estimates are lacking. We addressed this in a study-level meta-analysis of two large, recent cohort studies that used Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) project and Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium data. - Source: PubMed
Publication date: 2026/06/03
Allen IsaacWhish NancyYadav SiddharthaBoddicker Nicholas JDrukker Carolinevan de Beek IrmaEccles Diana MTurnbull ClarePharoah PaulAntoniou Antonis CEaston Douglas FCouch Fergus JSchmidt Marjanka KTischkowitz Marc - Germline testing is underutilized and varies by cancer diagnosis. We hypothesized that patient and clinician involvement in cascade testing of relatives varies by the cancer susceptibility (breast gastrointestinal [GI]) of the affected gene. - Source: PubMed
Publication date: 2026/06/03
Kurian Allison WAbrahamse PaulFurgal AllisonVeenstra Christine MCourser Rebecca RHofer Timothy PHodan RachelCaswell-Jin Jennifer LGomez Scarlett LWard Kevin CHamilton Ann SLiu LihuaAn Lawrence CKatz Steven J - Germline variants in cancer predisposition genes have been increasingly recognized in pediatric cancers. However, their spectrum in East Asian children with central nervous system (CNS) tumors remains insufficiently defined. This study investigated the prevalence and clinical significance of pathogenic or likely pathogenic (P/LP) germline mutations in Korean children, adolescents, and young adults (AYAs) with CNS tumors. We performed targeted next-generation sequencing of 358 cancer-associated genes using peripheral blood DNA from 108 patients. Germline variants were classified according to ACMG/AMP guidelines and curated using ClinVar and relevant literature. Among 108 patients, 17 (15.7%) carried P/LP germline variants. The median age at diagnosis was 7.7 years (range, 1.0-24.0), and 64.7% were male. P/LP variants were most frequent in other CNS tumors (4/11, 36.4%), including 2 glioneuronal tumors, 1 schwannoma, 1 atypical teratoid rhabdoid tumor (ATRT), and gliomas (9/32, 28.1%), followed by medulloblastomas (3/31, 9.7%). In gliomas, P/LP variants in MLH1, NF1, MUTYH, PALB2, PMS2, FANCM, and TP53 were observed, while medulloblastomas carried alterations in SUFU, BRIP1, and FANCI. SMARCB1 variant was found in ATRT. Among 25 patients with intracranial germ cell tumors, only a single case carried a P/LP germline variant, identified in FANCI. Germline P/LP mutations were identified in 15.7% of Korean children and AYAs with CNS tumors, most commonly in gliomas and other CNS tumors. Our findings highlight the molecular heterogeneity of germline predisposition in CNS tumors and emphasize the importance of germline testing for risk assessment and surveillance. - Source: PubMed
Publication date: 2026/05/21
Park MeerimPark SeungmanOh EnselChoi JongmunKwon Mi MiPark Seog-YunLee Jun AhPark Hyeon Jin